121 related articles for article (PubMed ID: 2276394)
1. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics of chlorpropamide.
Kallio J; Huupponen R; Pyykkö K
Eur J Clin Pharmacol; 1990; 39(1):93-5. PubMed ID: 2276394
[TBL] [Abstract][Full Text] [Related]
2. Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation.
Danhof M; Idle JR; Teunissen MW; Sloan TP; Breimer DD; Smith RL
Pharmacology; 1981; 22(6):349-58. PubMed ID: 7267701
[TBL] [Abstract][Full Text] [Related]
3. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
Kallio J; Lindberg R; Huupponen R; Iisalo E
Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
[TBL] [Abstract][Full Text] [Related]
4. Genetically determined oxidation capacity and the disposition of debrisoquine.
Sloan TP; Lancaster R; Shah RR; Idle JR; Smith RL
Br J Clin Pharmacol; 1983 Apr; 15(4):443-50. PubMed ID: 6849780
[TBL] [Abstract][Full Text] [Related]
5. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.
Lennard MS; Jackson PR; Freestone S; Tucker GT; Ramsay LE; Woods HF
Br J Clin Pharmacol; 1984 Jun; 17(6):679-85. PubMed ID: 6743465
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
Bertilsson L; Dengler HJ; Eichelbaum M; Schulz HU
Eur J Clin Pharmacol; 1980 Feb; 17(2):153-5. PubMed ID: 7371707
[TBL] [Abstract][Full Text] [Related]
7. Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypes.
Dahl-Puustinen ML; Alm C; Bertilsson L; Christenson I; Ostman J; Thunberg E; Wikström I
Br J Clin Pharmacol; 1990 Sep; 30(3):476-80. PubMed ID: 2121211
[TBL] [Abstract][Full Text] [Related]
8. Relation between debrisoquine oxidation phenotype and morphological, biological, and pathological variables in a large population.
Vincent-Viry M; Muller J; Fournier B; Galteau MM; Siest G
Clin Chem; 1991 Mar; 37(3):327-32. PubMed ID: 2004438
[TBL] [Abstract][Full Text] [Related]
9. Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine.
Lledó P; Abrams SM; Johnston A; Patel M; Pearson RM; Turner P
Eur J Clin Pharmacol; 1993; 44(1):63-7. PubMed ID: 8436157
[TBL] [Abstract][Full Text] [Related]
10. Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans.
Dahl ML; Ekqvist B; Widén J; Bertilsson L
Acta Psychiatr Scand; 1991 Jul; 84(1):99-102. PubMed ID: 1927573
[TBL] [Abstract][Full Text] [Related]
11. Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype.
Peart GF; Boutagy J; Shenfield GM
Eur J Clin Pharmacol; 1987; 33(4):397-402. PubMed ID: 3443146
[TBL] [Abstract][Full Text] [Related]
12. Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine.
Wanwimolruk S; Chalcroft S
Br J Clin Pharmacol; 1991 Nov; 32(5):617-20. PubMed ID: 1954076
[TBL] [Abstract][Full Text] [Related]
13. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers.
Llerena A; Dahl ML; Ekqvist B; Bertilsson L
Ther Drug Monit; 1992 Jun; 14(3):261-4. PubMed ID: 1412613
[TBL] [Abstract][Full Text] [Related]
14. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.
Brynne N; Dalén P; Alván G; Bertilsson L; Gabrielsson J
Clin Pharmacol Ther; 1998 May; 63(5):529-39. PubMed ID: 9630826
[TBL] [Abstract][Full Text] [Related]
15. Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics and first dose effect of prazosin.
Lennard MS; McGourty JC; Silas JH
Br J Clin Pharmacol; 1988 Feb; 25(2):276-8. PubMed ID: 3358891
[TBL] [Abstract][Full Text] [Related]
16. Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation.
Dayer P; Leemann T; Küpfer A; Kronbach T; Meyer UA
Eur J Clin Pharmacol; 1986; 31(3):313-8. PubMed ID: 2878813
[TBL] [Abstract][Full Text] [Related]
17. Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation.
Sloan TP; Idle JR; Smith RL
Clin Pharmacol Ther; 1981 Apr; 29(4):493-7. PubMed ID: 7471615
[TBL] [Abstract][Full Text] [Related]
18. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.
Lennard MS; Silas JH; Freestone S; Trevethick J
Br J Clin Pharmacol; 1982 Aug; 14(2):301-3. PubMed ID: 6125207
[TBL] [Abstract][Full Text] [Related]
19. The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.
Lennard MS; Tucker GT; Woods HF
Clin Pharmacokinet; 1986; 11(1):1-17. PubMed ID: 2868819
[TBL] [Abstract][Full Text] [Related]
20. Deficient metabolism of debrisoquine and sparteine.
Inaba T; Otton SV; Kalow W
Clin Pharmacol Ther; 1980 Apr; 27(4):547-9. PubMed ID: 7357813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
